JAP15 Rec'd PCT/PTO 21 FEB 2007

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

6. '

	ANSMITTAL LETTER TO	ATTORNEY'S DOCKET NUMBER PP020110.0005/59516-313					
DESIGNATED/ELECTED OFFICE (DO/EO/US)			U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371			10/566,410				
	TONAL APPLICATION NO. 2004/017921	INTERNATIONAL FILING DATE 04 June 2004 (04.06.2004)	PRIORITY DATE CLAIMED 30 July 2003 (30.07.2003)				
	N. 10 (CA 10 A 1	PY FOR CHRONIC LYMPHOCYTIC LE	EUKEMIA				
APPLICAN	APPLICANT(S) FOR DO/EO/US Deborah HURST, et al.						
Applicant	herewith submits to the United Sta	ates Designated/Elected Office (DO/EC	D/US) the following items and other information:				
1. 🔲 1	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.						
2. 🗸 1	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.						
3. 🗸 т	his is an express request to begin nation (5), (6), (9) and (21) indicated below.	onal examination procedures (35 U.S.C. 37	1(f)). The submission must include items				
4. 🗸	The US has been elected (Article 31).						
5. 🗸	A copy of the International Application	n as filed (35 U.S.C. 371(c)(2))					
	a. is attached hereto (required	only if not communicated by the Internation	nal Bureau).				
	b. has been communicated by						
		cation was filed in the United States Receive					
6. 🗀	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
	a. is attached hereto.						
	b. has been previously submitted under 35 U.S.C. 154(d)(4).						
7. ✓	r—	rnational Application under PCT Article 19					
	F***	red only if not communicated by the Interna	tional Bureau).				
		by the International Bureau.					
		ever, the time limit for making such amendr	nents has NOT expired.				
. \Box	d. have not been made and v		ticle 19 (35 I I S.C. 371(c)(3))				
9.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT						
	Article 36 (35 U.S.C. 371(c)(5)).						
r	ns 11 to 20 below concern document(s) or information included:						
11. 🔲	An Information Disclosure Statement		ith 37 CER 3 28 and 3 31 is included				
12. 13. 	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13. 🖸	A preliminary amendment.						
15.	An Application Data Sheet under 37 CFR 1.76.						
16.	A substitute specification. A power of attorney and/or change of address letter.						
17.	A power or attorney and/or change or address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter.</i> 2 and 37 CFR 1.821- 1.825.						
18.		national Application under 35 U.S.C. 154(d)					
19.		ge translation of the international application					
15	A second coby or the English langual	go dandida or ano international appropriation					

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007, OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/566,410			INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER		
				PCT/US2004/017921	PCT/US2004/017921			PP020110.0005/59516-313	
	20. Other items or information: Copy of 371 Formalities Letter; Petition Under 37 CFR 1.47(a); Declaration of Lisa Nash w/Exhbits A-D; Petition for Extension of Time (+								
	copy); Petition Fee Transmittal (+ copy); Statement in Response to Sequence Requirement; return receipt postcard								
ı		The following fees have been submitted							PTO USE ONLY
1	21. Basi	c national fee (37	CFR 1.492(a))			\$300	\$		
ı	22. Exam	2. Examination fee (37 CFR 1.492(c))							
	hy IPFA/	If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)					\$		
	If the written opin IPEA/US Search fee (37 C International Sea previously						\$		
							\$0		
	Additional fe sequenc electroni	TOTAL OF 21, 22 and 23 = Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compilance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.							
				additional 50 or fraction up to a whole number)	RA	RATE			
	- 100 =	- 100 = /50 =			x \$250		\$		
	Surcharge of \$130.00 for furnishing any of the search after the date of commencement of the national stage			n fee, examination fee, or the e (37 CFR 1.492(h)).	e oath or	declaration	\$ 130.00		
	CLAIMS	NUM	BER FILED	NUMBER EXTRA	TRA RATE		\$		
	Total claims		32 - 20 =	12	x	\$ 50	\$ 60	00.00	
	Independent clai	ms	7 -3=	4	х	\$200	\$ 80	00.00	
	MULTIPLE DEPI	ENDENT CLAIM	ENT CLAIM(S) (if applicable) + \$360			\$360	\$	0.00	
	TOTAL OF ABOVE CALCULATIONS =					\$ 140	00.00		
	Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.								
	SUBTOTAL =				\$ 1530.00				
Processing fee of \$130.00 for furnishing the English translation later than 30 months claimed priority date (37 CFR 1.492(i)).						+	\$ 0.00		
	TOTAL NATIONAL FEE =					\$ 1530.00			
	Fee for recording by an appropriate	ee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied y an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 0.00			
,	LANDGRA 00000	00000003 040258 10566410 TOTAL FEES ENCLOSED =			\$ 1530.00				
,		130.00 DA				Amount to be refunded:		\$	
í	800.00	W 1 1					Amount to be charged		\$

а. 🔲	A check in the amount of \$ to cover the above fees is enclosed.						
b. 🗸	Please charge my Deposit Account No. 04-0258 in the amount of \$ 1530.00 to cover the above fees. A duplicate copy of this sheet is enclosed.						
c. 🗸	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>04-0258</u> . A duplicate copy of this sheet is enclosed.						
d. 🔲	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card Information should not be Included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: W	NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.						
SEND AL	SEND ALL CORRESPONDENCE TO:						
	right Tremaine LLP SIGNATURE						
2600 Ce	ntury Square						
	urth Avenue Washington 98101-1688 NAME						
UNITED	STATES OF AMERICA 33,332 33,332						
	(206) 622-3150 e: (206) 628-7699						



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Sox 1459 Alexandria, Virginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLIC	ANT	ATTY. DOCKET NO.		
10/566,410	Deborah Hurst	P	PP020110000559516313		
		INTERNATIO	ONAL APPLICATION NO.		
		PCT	PCT/US04/17921		
Davis Wright Tremaine		I.A. FILING D	ATE PRIORITY DATE		
2600 Century Square	RECEIVED	06/04/200	07/30/2003		

Seatle, WA 98101-1688

JUL 2 5 2006

CONFIRMATION NO. 5534 371 FORMALITIES LETTER

OC000000019708608

Date Mailed: 07/21/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 01/30/2006
- Copy of the International Search Report filed on 01/30/2006
- U.S. Basic National Fees filed on 01/30/2006
- Priority Documents filed on 01/30/2006
- Specification filed on 01/30/2006
- Claims filed on 01/30/2006
- Abstracts filed on 01/30/2006
- Drawings filed on 01/30/2006

ENTERED IN DWT

JUL 262006

The applicant needs to satisfy supplemental fees problems indicated below.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of \$960 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$1090 for a Large Entity:

- \$130 Surcharge.
 - This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- Total additional claim fee(s) for this application is \$ 960
 - **\$600** for **31** total claims over 20.
 - \$360 for multiple dependent claim surchare.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMB	ER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/566.410		PCT/US04/17921	PP020110000559516313

FORM PCT/DO/EO/905 (371 Formalities Notice)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Deborah Hurst et al.

Application No.

10/566,410 (U.S. National Phase of PCT/US04/17921)

§ 371 Date

January 30, 2006

For

METHODS OF THERAPY FOR CHRONIC LYMPHOCYTIC

LEUKEMIA

Docket No. :

59516-313

Date

February 21, 2007

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT IN RESPONSE TO SEQUENCE REQUIREMENT

Commissioner for Patents:

Applicants submit that no Sequence Listing is required for this application. 37 C.F.R. § 1.821(a) defines a sequence, in part, as four or more amino acids, or ten or more nucleotides. Applicants request that the Patent Office indicate where in the application such sequences appear. No Sequence Listing was filed with the International application because applicants believed that the specification does not contain sequence disclosure that falls within the requirements of 37 C.F.R. § 1.821(a).

Respectfully submitted, Davis Wright Tremaine LLP

Ør. Jane E.R. Potter, Esq. Registration No. 33,332

2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688 Phone: (206) 622-3150 Facsimile: (206) 628-7699